Targeting focal adhesion kinase inhibits cell migration and non-angiogenic vascularization in malignant breast cancer
Breast Cancer · 2026
DOI: 10.1007/s12282-025-01792-6 ↗Kurz gefasst
Fachartikel in der Zeitschrift Breast Cancer, 2026. Verfasst von Misato Masuyama und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Breast and Endocrine Surgery, The University of Osaka Graduate School of Medicine, 2-2-E10, Yamadaoka, Suita, Osaka, 565-0871, Japan. Hauptthemen laut MEDLINE: Breast Neoplasms, Cell Movement, Neovascularization, Pathologic, Protein Kinase Inhibitors. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Society for the Promotion of Science.
Abstract (Originalsprache)
Background
High-grade carcinomas, including breast cancer, are associated with angiogenesis and non-angiogenic vascularization. Non-angiogenic vascularization enhances blood flow, tumor growth, and metastasis. Although inhibition of focal adhesion kinase (FAK) is a promising anticancer strategy, its effect on non-angiogenic vascularization remains unknown. We aimed to determine if defactinib, an oral selective FAK inhibitor, suppresses tumor growth by inhibiting non-angiogenic vascularization via reduced cell migration in malignant breast cancer cell lines.
Methods
Non-angiogenic vascularization was evaluated in JIMT-1 and MDA-MB-231 cells. Western blotting, fluorescent immunocytochemistry, cell migration assay, time-lapse microscopy, and tube formation assays were performed to evaluate the effects of defactinib. Cells were transfected with siFAK to evaluate off-target effects. The in vivo effects were assessed in orthotopic mouse tumor models, followed by immunohistochemical staining of excised tumor samples.
Results
Defactinib induced changes in cell morphology, migration, and the formation of vascular-like structures in JIMT-1 and MDA-MB-231 cells. Phosphorylation of FAK/PTK2 and its downstream effectors was reduced in defactinib-treated cells. SiRNA-mediated FAK knockdown produced similar effects. Treatment with defactinib suppressed tumor growth in orthotopic mouse tumor models, resulting in tumor shrinkage and reduced macroscopic blood-rich areas. Immunohistochemical staining also revealed a significant reduction in the number of vessels characterized by human serpin family E member 2—a potential indicator of non-angiogenic vascularization—in the defactinib-treated group, with no significant increase in apoptosis.
Conclusions
FAK inhibition was shown to suppress non-angiogenic vascularization. Defactinib has the potential to serve as a novel treatment for malignant breast cancer which is resistant to conventional therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Breast and Endocrine Surgery, The University of Osaka Graduate School of Medicine, 2-2-E10, Yamadaoka, Suita, Osaka, 565-0871, Japan.
- Department of Breast and Endocrine Surgery, The University of Osaka Graduate School of Medicine, 2-2-E10, Yamadaoka, Suita, Osaka, 565-0871, Japan. mshimoda@onsurg.med.osaka-u.ac.jp.
Förderung
- Japan Society for the Promotion of Science
Zitieren
APA
Masuyama, M., Shimoda, M., Seto, I., Kikumori, K., Abe, K., Masunaga, N., Mishima, C., Tsukabe, M., Yoshinami, T., Sota, Y., Miyake, T., Tanei, T., & Shimazu, K. (2026). Targeting focal adhesion kinase inhibits cell migration and non-angiogenic vascularization in malignant breast cancer. Breast Cancer. https://doi.org/10.1007/s12282-025-01792-6
Vancouver
Masuyama M, Shimoda M, Seto I, Kikumori K, Abe K, Masunaga N, et al. Targeting focal adhesion kinase inhibits cell migration and non-angiogenic vascularization in malignant breast cancer. Breast Cancer. 2026. doi:10.1007/s12282-025-01792-6
BibTeX
@article{Masuyama2026,
author = {Masuyama, Misato and Shimoda, Masafumi and Seto, Ikumi and Kikumori, Kaori and Abe, Kaori and Masunaga, Nanae and Mishima, Chieko and Tsukabe, Masami and Yoshinami, Tetsuhiro and Sota, Yoshiaki and Miyake, Tomohiro and Tanei, Tomonori and Shimazu, Kenzo},
title = {Targeting focal adhesion kinase inhibits cell migration and non-angiogenic vascularization in malignant breast cancer},
journal = {Breast Cancer},
year = {2026},
doi = {10.1007/s12282-025-01792-6}
}
EUVIMED